SwedenSweden

Biovitrum Acquires Oncology Project

09.10.2004

Stockholm - Biovitrum AB will acquire a promising oncology project from Axelar AB, a company established by leading researchers at the Karolinska Institute, and Karolinska Innovations AB. The project includes the development of molecules that inhibit the IGF-1 receptor, which is involved in the growth of tumour cells in several ways and may lead to future treatment opportunities for various types of cancer. Through the agreement, Biovitrum gets access to a new chemical entity against cancer, which has demonstrated promising results in pre-clinical studies. “The research done by Axelar is highly interesting and cutting edge. The IGF-1 receptor is a very promising target for cancer treatment,” says Terje Kalland, CSO of Biovitrum. The project will be further developed in collaboration between Biovitrum and Prof. Magnus Axelson and Prof. Olle Larsson, the researchers at the Karolinska Institute who spun-off Axelar AB. “We are very pleased to be able to work together with Biovitrum. The collaboration will give us an opportunity to succeed in our research for finding a new way to treat cancer,” stated Prof. Axelson and Prof. Larsson.

SwedenSweden

12.03.2012

Gothenburg – Researchers at the Sahlgrenska Academy have discovered a previously unknown mechanism which helps intestinal bacteria to affect the formation of blood vessels. In a study of mice, the team led by Fredrik Bäckhed...

SwedenSweden

08.03.2012

Swiss Nestlé S.A. has extended its collaboration agreement with BioGaia AB. The world’s largest nutrition company is paying up to €50.8m for a perpetual licence to use BioGaia’s patented Lacto­bacillus reuteri in infant nutrition...

SwedenSweden

08.03.2012

Stockholm – Swedish drug delivery specialist Orexo AB has announced the intention to cut its headcount by 30% in order to reduce the company's burn rate. The personnel reduction by 35 people is expected to lower the costs by a...

SwedenSweden

07.03.2012

After a long period of negotiations, Sweden’s Orexo AB and Belgium’s Janssen Pharmaceutica have terminated their joint research programmes. “Unfortunately, we lack the funds to continue on our own to develop the OX-CLI and OX-ESI...

SwedenSweden

06.03.2012

Uppsala/Moscow – Vaccine adjuvant specialist Isconova AB is set to begin receiving royalties and product revenues from Russian partner VetBioChem. The veterinary medicine company has launched two new rabies vaccines for dogs and...

SwedenSweden

23.02.2012

Stockholm - Probiotics can help prevent diseases, Swedish researchers have found out. The results are in sharp contrast with all health claim judgements involving probiotics published by the EU's food watchdog EFSA up to now. The...

SwedenSweden

16.02.2012

Huddinge – Full stop for one of Sweden's most promising biotech companies. Karo Bio has terminated the trial of its late-stage cholesterol drug eprotirome and won't proceed with its plans to spin off its preclinical operations....

SwedenSweden

19.12.2011

Helsingborg/Exton – Swedish drug developer DuoCort Pharma AB has been purchased by US-based biopharmaceuticals maker ViroPharma Inc. ViroPharma paid around €25m up front, but DuoCort’s former owners could end up receiving €97m...

SwedenSweden

15.12.2011

Stockholm/Cologne – Researchers at the Swedish Karolinska Institute and the University of Cologne have identified a new protein-based defense mechanism against cancer (Struct. & Molec. Biology, doi: 10.1038/10.1038/nsmb.2188)....

SwedenSweden

15.12.2011

Craigavon/Uppsala – Irish Almac Discovery, a member of the Almac Group, will begin cooperating with Uppsala-based Beactica AB to develop new cancer drug candidates. In late November, the companies announced that Beactica’s Sprint...

Displaying results 1 to 10 out of 182

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-sweden/article/biovitrum-acquires-oncology-project.html

Product of the week

Products

Events

All Events

Current issue

All issues